U.S. News Room
Thu Feb 19 00:00:00 GMT-05:00 2026
NEW
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
Download
Wed Feb 04 00:00:00 GMT-05:00 2026
NEW
DS3790 Enters Clinical Development as First DXd ADC in Hematology from Industry-Leading ADC Portfolio of Daiichi Sankyo
Download
Tue Feb 03 00:00:00 GMT-05:00 2026
NEW
DATROWAY Granted Priority Review in the US as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy
Download
Tue Jan 13 00:00:00 GMT-05:00 2026
TROPION-Lung17 TROP2 Biomarker Directed Phase 3 Trial of DATROWAY Initiated in Patients with Previously Treated Advanced Nonsquamous Non-Small Cell Lung Cancer
Download
Mon Dec 22 00:00:00 GMT-05:00 2025
ENHERTU Granted Breakthrough Therapy Designation in the US as Post-Neoadjuvant Therapy for Patients with HER2 Positive Early Breast Cancer
Download
Mon Dec 22 00:00:00 GMT-05:00 2025
DESTINY-Endometrial02 Phase 3 Trial of ENHERTU Initiated as Adjuvant Therapy in Patients with HER2 Expressing Endometrial Cancer
Download
Mon Dec 15 00:00:00 GMT-05:00 2025
ENHERTU Plus Pertuzumab Approved in the US as First New Treatment in More Than a Decade for First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer
Download
Tue Dec 09 00:00:00 GMT-05:00 2025
DESTINY-Ovarian01 Phase 3 Trial of ENHERTU Initiated as First-Line Maintenance Therapy in Patients with HER2 Expressing Advanced Ovarian Cancer
Download
Mon Dec 08 00:00:00 GMT-05:00 2025
Daiichi Sankyo Showcases Strength of Industry-Leading ADC Portfolio with Latest Research Updates from Five Landmark Breast Cancer Trials at SABCS
Download
Wed Dec 03 00:00:00 GMT-05:00 2025
Federal Circuit Court of Appeals Vacates Infringement Judgment and Damages Award in Dispute between Daiichi Sankyo and Seagen
Download